- The vaccine AZD1222 has reportedly triggered lower adverse response among elderly participants.
- Oxford’s and AstraZeneca’s COVID-19 vaccine could be the first candidate to receive a regulatory approval.
According to reliable sources, Oxford University’s COVID-19 vaccine candidate has displayed favorable results after producing immune response among both younger as well as adult participants.
The vaccine AZD1222, which is developed through a collaboration between University of Oxford and British pharmaceutical giant AstraZeneca plc, has reportedly also triggered lower adverse response among elderly participants, which is not the case with other vaccines under trial.
Sources with knowledge of the matter stated that the positive results emerged in data regarding safety & immune responses of study participants during Oxford’s phase II trials. The data included results of British volunteers of the age group 56-69 as well as that of over 70, which is likely to be formally published in the upcoming weeks.
According to the University of Oxford, the recently acquired results mark a milestone and provide assurance that the vaccine is not only safe to use, but also induces a strong immune response among individuals of all age groups.
It is to be noted that Oxford University and AstraZeneca have been conducting trials of their potential COVID-19 vaccine for months across the globe.
The potential vaccine could be a game changer in the battle against the COVID-19 pandemic, which has killed over 1.15 million people world over. In fact, Oxford’s and AstraZeneca’s COVID-19 vaccine could be the first candidate to receive a regulatory approval along with potential candidates like BioNtech as well as Pfizer.
Matt Hancock, British Health Secretary, was reported saying that although the vaccine is not ready yet, the department is preparing for essential logistics required for a possible roll out, mostly during the first half of the year 2021.
Meanwhile, staff at a major hospital in London have been informed to be prepared to receive the first batch of AstraZeneca and Oxford’s COVID-19 vaccine in first week of November, claimed sources with relevant information.
Source Credits –